Trade Gilead Sciences Inc - GILD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.92 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 91.65 |
| Open | 91.53 |
| 1-Year Change | 4.8% |
| Day's Range | 91.53 - 93.7 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 22, 2025 | 91.99 | 0.02 | 0.02% | 91.97 | 91.99 | 91.97 |
| Jan 21, 2025 | 91.97 | 0.46 | 0.50% | 91.51 | 93.84 | 90.55 |
| Jan 17, 2025 | 91.66 | 1.71 | 1.90% | 89.95 | 92.74 | 89.95 |
| Jan 16, 2025 | 89.95 | -2.01 | -2.19% | 91.96 | 93.01 | 89.95 |
| Jan 15, 2025 | 91.55 | 0.60 | 0.66% | 90.95 | 92.59 | 89.67 |
| Jan 14, 2025 | 91.44 | 2.41 | 2.71% | 89.03 | 91.44 | 88.75 |
| Jan 13, 2025 | 89.03 | -0.04 | -0.04% | 89.07 | 90.29 | 88.35 |
| Jan 10, 2025 | 89.63 | -0.53 | -0.59% | 90.16 | 91.34 | 88.52 |
| Jan 9, 2025 | 88.83 | 0.00 | 0.00% | 88.83 | 89.05 | 88.83 |
| Jan 8, 2025 | 88.84 | -1.49 | -1.65% | 90.33 | 90.65 | 88.83 |
| Jan 7, 2025 | 90.22 | -0.23 | -0.25% | 90.45 | 91.44 | 90.19 |
| Jan 6, 2025 | 90.45 | -0.68 | -0.75% | 91.13 | 91.44 | 89.71 |
| Jan 3, 2025 | 91.15 | 0.04 | 0.04% | 91.11 | 92.24 | 91.11 |
| Jan 2, 2025 | 91.11 | -0.52 | -0.57% | 91.63 | 92.90 | 91.11 |
| Jan 1, 2025 | 91.12 | 0.00 | 0.00% | 91.12 | 91.12 | 91.12 |
| Dec 31, 2024 | 91.12 | -0.63 | -0.69% | 91.75 | 92.88 | 90.98 |
| Dec 30, 2024 | 91.75 | -1.94 | -2.07% | 93.69 | 93.99 | 91.68 |
| Dec 27, 2024 | 94.12 | 0.97 | 1.04% | 93.15 | 94.40 | 92.79 |
| Dec 26, 2024 | 94.31 | 0.86 | 0.92% | 93.45 | 94.49 | 91.95 |
| Dec 24, 2024 | 93.80 | 1.85 | 2.01% | 91.95 | 93.96 | 91.95 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Gilead Company profile
What is Gilead Sciences?
What does the company do?
A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.
A bit of Gilead Sciences’ history
Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.
Who founded Gilead Sciences?
Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.
Current size, team and locations
Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.
Quick facts about Gilead Sciences
- Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
- It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
- In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
- In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.
How to learn the Gilead Sciences share price?
Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com